Research News


 2020-03-24

This resource on Type 1 Diabetes Research was created in partnership with JDRF, an active partner of Beyond Type 1 at the time of publication, through the JDRF – Beyond Type 1 Alliance.


 

Vertex VX-880 Clinical Results Lead To Insulin-Independence


Here's what you need to know about Vertex's recent results from their stem-cell therapy for type 1 diabetes.MORE

T1D Clinical Trial Search Engine Now Available In Spanish


Beyond Type 1 collaborates with Antidote Technologies and JDRF to launch the first-ever Spanish-language clinical trial search engine for type 1 diabetes.MORE
iLet Bionic Pancreas

Mounjaro Shows Multiple Benefits for Type 2 Diabetes Management


New, FDA-approved Mounjaro shows promising results for improving several aspects of type 2 diabetes management. MORE

Diabetes Game-Changer: A Once-Weekly Insulin


The development of a once-weekly insulin could simplify diabetes management for those with type 1 and type 2.MORE

Stem Cell Therapy for Type 1 Diabetes: Patient Achieved Insulin Independence on Day 270


A patient in the Vertex Pharmaceutical’s clinical trial using stem-cell therapy to treat type 1 diabetes has achieved insulin independence on Day 270 of the trial. MORE

Dedicated to Helping People With T1D: Dr. Gary Meininger on His Life and Career with Diabetes


We spoke with Dr. Meininger on his personal connection to T1D, his role at Vertex, and important work being done in clinical trials.MORE
vertex pharmaceuticals stem cell therapy for type 1 diabetes

Stem-Cell Therapy for Type 1 Diabetes Reduced Patient’s Insulin Needs by 91%


The early results of a clinical trial using stem-cell therapy to treat type 1 diabetes reduced the patient’s insulin needs by 91%.MORE
teplizumab

FDA Issues CRL for Teplizumab, Investigational Candidate to Delay the Onset of T1D


The FDA issues a complete response letter to Provention Bio as part of an update for Teplizumab to delay the onset of type 1 diabetes.MORE

The PROTECT Study 


The PROTECT Study aims to understand how the investigational medicine, teplizumab, works in children and young adults who have recently been diagnosed with T1D, as well as assessing if there are any s...MORE

JDRF Launches Program to Advance Universal Screening for Type 1 Diabetes


T1Detect is a new screening initiative designed to make early detection of type 1 diabetes easier and more accessible to a broad population. MORE

From Diagnosis Through Complications: Disparities in Diabetes Care


Recent research is confirming what many have experienced - that beginning at diagnosis, ethnic minorities in the US face more challenges navigating diabetes and care than their white counterparts. MORE

Omnipod Closed Loop Technology to be Compatible with Both Abbott and Dexcom CGMs


Abbott and Dexcom announced formal partnerships with Insulet to be compatible as CGMs on the Omnipod Horizon Automated Insulin Delivery System. MORE

New Evidence Shows Vital Importance of Screening For T1D in Children


By screening for type 1 diabetes in children, Bavaria was able to decrease rates of diabetic ketoacidosis at diagnosis.MORE

Tandem’s Control-IQ Hybrid Closed Loop Approved by the FDA


The FDA announced the approval of the Control-IQ Hybrid Closed Loop System from Tandem Diabetes Care. The system sees the t:slim X2 insulin pump and Dexcom G6 continuous glucose monitor working togeth...MORE

 


To learn more about all the great type 1 diabetes (T1D) research being funded by JDRF, visit their research and impact page here.

WRITTEN BY BT1 Editorial Team, POSTED 03/24/20, UPDATED 01/03/23

This piece was authored collaboratively by the Beyond Type 1 Editorial Team.